Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NX-019 |
Synonyms | |
Therapy Description |
NX-019 is a mutant-selective EGFR inhibitor with activity against EGFR exon 19 deletions, L858R, T790M, and exon 20 insertions, which potentially reduces tumor growth (Ann Oncol 2022, Vol 33, Suppl 9, Abstract # S1588). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NX-019 | NX019|NX 019 | EGFR Inhibitor (Pan) 62 | NX-019 is a mutant-selective EGFR inhibitor with activity against EGFR exon 19 deletions, L858R, T790M, and exon 20 insertions, which potentially reduces tumor growth (Ann Oncol 2022, Vol 33, Suppl 9, Abstract # S1588). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05514496 | Phase I | NX-019 | A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer | Recruiting | USA | 2 |